Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion
Publication date: Available online 23 June 2016 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Mireille Crampe, Jennifer Garry, Stephen E. Langabeer, Philip T. Murphy
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Nilotinib | Stem Cell Therapy | Stem Cells | Tasigna